Entrada Therapeutics, Inc. (TRDA)

$17.15

-0.22

(-1.27%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Entrada Therapeutics, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.1% return, outperforming this stock by 75.0%

Performance

  • $16.72
    $18.00
    $17.15
    downward going graph

    2.51%

    Downside

    Day's Volatility :7.11%

    Upside

    4.72%

    downward going graph
  • $10.75
    $18.44
    $17.15
    downward going graph

    37.32%

    Downside

    52 Weeks Volatility :41.7%

    Upside

    7.0%

    downward going graph

Returns

PeriodEntrada Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
33.05%
6.7%
0.0%
6 Months
14.87%
5.5%
0.0%
1 Year
6.13%
14.3%
0.0%
3 Years
-28.39%
15.1%
-21.0%

Highlights

Market Capitalization
531.4M
Book Value
$8.53
Earnings Per Share (EPS)
0.69
PE Ratio
22.81
Wall Street Target Price
21.5
Profit Margin
14.42%
Operating Margin TTM
35.71%
Return On Assets TTM
3.01%
Return On Equity TTM
9.41%
Revenue TTM
162.9M
Revenue Per Share TTM
4.89
Quarterly Revenue Growth YOY
134.0%
Gross Profit TTM
0.0
EBITDA
27.0M
Diluted Eps TTM
0.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
-3.52
EPS Estimate Current Quarter
-0.59
EPS Estimate Next Quarter
-0.58

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Entrada Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 25.36%

Current $17.15
Target $21.50

Technicals Summary

Sell

Neutral

Buy

Entrada Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.
4.26%
14.87%
6.13%
-28.39%
-28.39%
Moderna, Inc.
Moderna, Inc.
-16.37%
18.89%
-4.07%
-48.35%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.16%
17.36%
52.58%
90.65%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
-0.29%
33.6%
81.13%
227.9%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.03%
11.71%
40.03%
146.43%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.
22.81
22.81
NA
-0.5
0.09
0.03
NA
8.53
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc.
Buy
$531.4M
-28.39%
22.81
14.42%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Institutional Holdings

  • Baker Bros Advisors LP

    14.41%
  • Mpm Asset Management, LLC

    13.11%
  • 5AM Venture Management, LLC

    13.06%
  • T. Rowe Price Associates, Inc.

    8.16%
  • BlackRock Inc

    4.40%
  • Redmile Group, LLC

    3.80%

Company Information

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.

Organization
Entrada Therapeutics, Inc.
Employees
160
CEO
Mr. Dipal Doshi
Industry
Services

FAQs